Who are AK112 high dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nivolumab in combination with Ipilimumab, Neoadjuvant ipilimumab + nivolumab, Nivolumab & Ipilimumab, APVO101, AK102, Adjuvant Nivolumab and Ipilimumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ak112-high-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

AK112 high dose — Competitive Intelligence Brief

AK112 high dose (AK112 high dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific checkpoint inhibitor. Area: Oncology.

phase 2 Bispecific checkpoint inhibitor PD-1 and CTLA-4 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AK112 high dose (AK112 high dose) — Akeso. AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and CTLA-4 to enhance anti-tumor immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AK112 high dose TARGET	AK112 high dose	Akeso	phase 2	Bispecific checkpoint inhibitor	PD-1 and CTLA-4
Nivolumab in combination with Ipilimumab	Nivolumab in combination with Ipilimumab	Bristol-Myers Squibb	marketed	Checkpoint inhibitor combination (PD-1 inhibitor + CTLA-4 inhibitor)	PD-1 and CTLA-4
Neoadjuvant ipilimumab + nivolumab	Neoadjuvant ipilimumab + nivolumab	The Netherlands Cancer Institute	phase 3	Immune checkpoint inhibitor combination	PD-1 and CTLA-4
Nivolumab & Ipilimumab	Nivolumab & Ipilimumab	The First Affiliated Hospital of Guangzhou Medical University	phase 3	PD-1 inhibitor + CTLA-4 inhibitor combination	PD-1 and CTLA-4
APVO101	APVO101	Medexus Pharma, Inc.	phase 3	Dual checkpoint inhibitor	PD-1 and CTLA-4
AK102	AK102	Akeso	phase 3	Bispecific checkpoint inhibitor	PD-1 and CTLA-4
Adjuvant Nivolumab and Ipilimumab	Adjuvant Nivolumab and Ipilimumab	Universitätsklinikum Hamburg-Eppendorf	phase 3	PD-1 inhibitor and CTLA-4 inhibitor combination	PD-1 and CTLA-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific checkpoint inhibitor class)

Akeso · 3 drugs in this class
Bio-Thera Solutions · 3 drugs in this class
Innovent Biologics (Suzhou) Co. Ltd. · 2 drugs in this class
Fujifilm Kyowa Kirin Biologics Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AK112 high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/ak112-high-dose. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab